<DOC>
	<DOCNO>NCT00537953</DOCNO>
	<brief_summary>The combination half-course miltefosine half-course antimony evaluate efficacy tolerance . The combination miltefosine antimony choose two standard agent Bolivia , vitro combination additive mildly synergistic standard leishmania strain .</brief_summary>
	<brief_title>Short Course Miltefosine Antimony Treat Cutaneous Leishmaniasis Bolivia</brief_title>
	<detailed_description>Combination therapy use many infectious disease , tuberculosis , malaria , HIV . Combination therapy offer potential prevent drug resistance , organism resistant one drug may susceptible drug ; also potential diminish drug therapy duration thus side effect . These two potential benefit extent contradict : preventing resistance best do full course drug use ; diminish therapy duration mean use le full course drug . The optimum combination regimen one sufficient amount drug use high efficacy , yet amount low possible spare patient unnecessarily long courses drug . Until recently , standard treatment leishmaniases pentavalent antimony ( Glucantime Pentostam ) . The cure rate L panamensis Colombia 91 % -93 % [ Soto , 1993 ; Velez , 1997 ] cure rate Bolivia , work soon complete , also 90 % [ Soto , unpublished result ] . A large study several formulation antimony find combined Bolivia-Colombia cure rate 86 % [ Soto , 2004b ] . Nevertheless , pentavalent antimonials disadvantage multiple injection mild-moderate clinical toxicity [ gastrointestinal complaint , liver enzyme elevation , pancreatic enzyme elevation ] , particularly unpleasant moderate clinical problem cutaneous leishmaniasis . The oral agent Miltefosine show effective antimony Colombia Bolivia . In Colombia , cure rate miltefosine 91 % [ Soto 2004a ] soon complete comparative trial Bolivia , cure rate miltefosine appear 92 % [ Soto , unpublished result ] . Side effect see patient cutaneous disease specifically attribute drug nausea vomit mild grade approximately 25 % patient , low-grade elevation creatinine also approximately 25 % patient [ Soto 2001 ; Soto 2004 ] . A disadvantage miltefosine regimens short 4 week evaluate cutaneous disease .</detailed_description>
	<mesh_term>Leishmaniasis</mesh_term>
	<mesh_term>Leishmaniasis , Cutaneous</mesh_term>
	<mesh_term>Meglumine antimoniate</mesh_term>
	<mesh_term>Miltefosine</mesh_term>
	<criteria>Gender : Male Age : Adults Presentation : At least 1 lesion must ulcerative . Parasitology : Parasitological confirmation 1 lesion make visualization culture leishmania biopsy aspirate lesion . Previous treatment leishmaniasis , specific putatively specific therapy ( Sb , pentamidine , amphotericin B , imidazole , allopurinol ) Other concomitant disease history approximately normal complete blood count ( white blood count , hemoglobin , platelet count ) , value liver transaminase ( SGOT ) , value pancreatic function ( lipase ) , kidney function test ( creatinine ) , EKG .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2007</verification_date>
	<keyword>Leishmaniasis</keyword>
	<keyword>Cutaneous leishmaniasis</keyword>
	<keyword>Miltefosine</keyword>
	<keyword>Glucantime</keyword>
	<keyword>Antimony</keyword>
	<keyword>Pentavalent antimonials</keyword>
	<keyword>Combination therapy</keyword>
</DOC>